SAFETY DATA SHEETS

This SDS packet was issued with item:

078929405

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078929400 078929401 078929402 078929403 078929404



SAFETY DATA SHEET

1. Identification

Product identifier Galliprant Tablets

Other means of identification

Item Code CA5810, CA5811, CA5812 Veterinary Pharmaceutical Recommended use

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information Elanco Animal Health **Company Name** 2500 Innovation Way Greenfield, IN 46140

US

Phone: 1-877-Elanco1 (1-877-352-6261)

Emergency Telephone: Elanco Product Technical Support / Human or Animal Exposure Reporting:

1-888-545-5973

elanco_sds@elanco.com Email: CHEMTREC: 1-800-424-9300 **Transportation Emergency** (Outside U.S. 1-703-527-3887) Telephone:

2. Hazard(s) identification

Physical hazards Not classified. **Health hazards** Not classified. **OSHA** defined hazards Not classified.

Label elements

Hazard symbol None. None. Signal word

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Not available. Prevention Not available. Response Not available. Storage Not available. **Disposal** Hazard(s) not otherwise None known.

classified (HNOC)

Supplemental information None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Grapiprant	Benzenesulfonamide, N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H- imidazo[4,5-c]pyridin—1-yl)phenyl]ethyl]a mino]carbonyl-4- methyl- N-[[[2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo [外,5db]-1-yl)phenyl]ethyl]amino]carbonyl]- 4 methylbenzenesulfonamide	415903-37-6	8

Remaining components of this product are non-hazardous and/or are present at concentrations **Composition comments**

below reportable levels.

Material name: Galliprant Tablets SDS US

6581 Version #: 03 Revision date: 12-21-2018 Issue date: 01-24-2017

4. First-aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Rinse with water. Get medical attention if irritation develops and persists. Eye contact

Ingestion Rinse mouth. Get medical attention if symptoms occur.

Most important

symptoms/effects, acute and

delayed

None known.

Indication of immediate medical attention and special

treatment needed

Treat symptomatically.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted. General fire hazards

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away.

Methods and materials for containment and cleaning up

Stop the flow of material, if this is without risk. Following product recovery, flush area with water.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling Conditions for safe storage, including any incompatibilities Observe good industrial hygiene practices. Store in original tightly closed container.

8. Exposure controls/personal protection

Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

Eye/face protection Wear safety glasses with side shields (or goggles).

Skin protection

Hand protection Wear appropriate chemical resistant gloves.

Other Wear suitable protective clothing.

Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment.

Thermal hazards Not available.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

Material name: Galliprant Tablets SDS US 2/5 6581 Version #: 03 Revision date: 12-21-2018 Issue date: 01-24-2017

9. Physical and chemical properties

Appearance

Solid. Physical state Tablet. **Form**

Color Brown (speckled) Not available. Odor **Odor threshold** Not available. Not available. pН Melting point/freezing point Not available. Not available. Initial boiling point and boiling

range

Flash point Not available. **Evaporation rate** Not available.

No test data available. Flammability (solid, gas)

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Not available. Explosive limit - lower (%) Explosive limit - upper (%) Not available. Not available. Vapor pressure Vapor density Not available.

Relative density Solubility(ies)

Solubility (water)

Not available.

Not available.

Partition coefficient (n-octanol/water)

Not available.

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. **Viscosity**

Other information

Explosive properties Not explosive. **Oxidizing properties** Not oxidizing.

10. Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport. Reactivity

Material is stable under normal conditions. **Chemical stability**

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Contact with incompatible materials. Conditions to avoid

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Based on available data, the classification criteria are not met. **Acute toxicity**

Components **Species Test Results**

Grapiprant (CAS 415903-37-6)

LD Rat 2000 mg/kg

No skin irritation. Skin corrosion/irritation

Material name: Galliprant Tablets

6581 Version #: 03 Revision date: 12-21-2018 Issue date: 01-24-2017

Serious eye damage/eye

irritation

No eye irritation.

Respiratory or skin sensitization

Respiratory sensitization Due to lack of data the classification is not possible.

Skin sensitization Not a skin sensitizer.

Germ cell mutagenicity In vitro and in vivo tests did not show mutagenic effects. (active ingredient)

Based on available data, the classification criteria are not met.

Carcinogenicity Due to lack of data the classification is not possible.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity Due to lack of data the classification is not possible.

Specific target organ toxicity -

single exposure

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

repeated exposure

Animal studies have reported the following effects: Gastrointestinal effects. (at high doses) (active

ingredient)

Based on available data, the classification criteria are not met.

Aspiration hazard Not an aspiration hazard.

12. Ecological information

Ecotoxicity No ecotoxicity data noted for the ingredient(s).

Persistence and degradability No data is available on the degradability of this product.

Bioaccumulative potential

Mobility in soilNo data available.Other adverse effectsNot available.

13. Disposal considerations

Disposal instructionsDispose of contents/container in accordance with local/regional/national/international regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Not

Not applicable.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulationsThis product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Material name: Galliprant Tablets sps us

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

(SDWA)

Not regulated.

US state regulations

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*CanadaDomestic Substances List (DSL)NoCanadaNon-Domestic Substances List (NDSL)NoUnited States & Puerto RicoToxic Substances Control Act (TSCA) InventoryNo

16. Other information, including date of preparation or last revision

 Issue date
 01-24-2017

 Revision date
 12-21-2018

Version # 03

Disclaimer

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:

Elanco Animal Health 0011+1-877-352-6261 0011+1-800-428-4441

Material name: Galliprant Tablets sps us

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).